Management of Cancer-Associated Thrombosis in France: A National Survey among Vascular Disease and Supportive Care Specialists

SIMPLE SUMMARY: Patients with venous thromboembolism events in the context of cancer should receive anticoagulants for at least 6 months. Both low molecular weight heparins (LMWHs) and direct oral anticoagulants (DOACs) are considered in international guidelines, with a different approach. To invest...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahé, Isabelle, Chapelle, Céline, Plaisance, Ludovic, Bertoletti, Laurent, Mismetti, Patrick, Mayeur, Didier, Mahé, Guillaume, Couturaud, Francis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454850/
https://www.ncbi.nlm.nih.gov/pubmed/36077680
http://dx.doi.org/10.3390/cancers14174143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454850/
https://www.ncbi.nlm.nih.gov/pubmed/36077680
http://dx.doi.org/10.3390/cancers14174143

Ejemplares similares